Physician profile
Munir Loya
NPI 1720070121
$2,474.24
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $1,027 · 2021: $306 · 2022: $270 · 2023: $432 · 2024: $27.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $900.00 | 2020 | |
| Amarin Pharma, INC. | $207.42 | 2019-2020 | |
| Medtronic, INC. | $171.97 | 2023 | Turbohawk |
| Astrazeneca Pharmaceuticals Lp | $124.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $124.05 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $100.08 | 2022-2023 | Mounjaro |
| Pfizer INC. | $84.70 | 2019-2022 | |
| Abbvie INC. | $84.17 | 2021-2024 | |
| Astellas Pharma US INC | $78.41 | 2019-2023 | Veozah |
| Optinose US, INC. | $65.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.22 | 2021-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $52.91 | 2023 | Arexvy, Shingrix |
| Abbott Laboratories | $47.46 | 2022 | |
| Currax Pharmaceuticals LLC | $42.07 | 2020 | |
| Xeris Pharmaceuticals, INC. | $40.69 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $35.18 | 2021 | |
| Inspire Medical Systems, INC. | $34.09 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.30 | 2022 | |
| Horizon Therapeutics Plc | $23.67 | 2019 | |
| Novo Nordisk INC | $23.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.21 | 2023 | |
| Esperion Therapeutics, INC. | $22.12 | 2021 | |
| Exact Sciences Corporation | $22.11 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $19.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.40 | 2022 | |
| Nevro Corp. | $14.51 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $13.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Loya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.